Hillstream BioPharma (HILS) Stock Price, News & Analysis

Company Overview

Hillstream BioPharma is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for the prevention and treatment of metastatic solid tumors. The company’s proprietary platform harnesses platelet biology to target and deliver therapeutic agents directly to the tumor microenvironment, with the goal of enhancing anti-tumor efficacy while minimizing off-target toxicity. Through its research pipeline, Hillstream advances both antibody-based and small molecule candidates designed to disrupt key interactions between tumor cells, platelets and immune effectors.

The company’s lead program, HIL-101, is a bispecific antibody that binds P-selectin on activated platelets and a tumor-associated antigen to facilitate localized immune activation. In parallel, Hillstream is developing HIL-102, a small molecule inhibitor aimed at blocking platelet-driven immunosuppression within metastatic niches. Both candidates have shown promising preclinical activity in models of breast, lung and colorectal cancer, and the company is preparing to initiate first-in-human studies under its investigational new drug applications.

Founded in 2015 and headquartered in Suzhou, China, Hillstream BioPharma also maintains a research hub in Houston, Texas, to support its translational activities and global clinical strategy. The company collaborates with leading academic institutions and contract research organizations across North America and Asia, leveraging a network of partnerships to accelerate its development timeline. Hillstream’s cross-border approach aims to bring its platelet-targeting technology to patients worldwide.

Hillstream BioPharma is led by Chairman and Chief Executive Officer Dr. Paul Hao, a veteran of the oncology drug development field, and Chief Scientific Officer Dr. Lina Chen, who brings extensive expertise in immuno-oncology and translational research. The management team is complemented by industry-seasoned executives in regulatory affairs, clinical operations and manufacturing, positioning the company to advance its innovative portfolio through key clinical milestones.

Key Stats

• Today's Range: $1.71 to $1.80
• 50-Day Range: $1.29 to $1.86
• 52-Week Range: $0.19 to $2.65
• Volume: 18,514 shs
• Average Volume: 1.39 million shs
• Market Capitalization: $30.45 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

HILS Stock Analysis - Frequently Asked Questions

How have HILS shares performed this year?

Hillstream BioPharma's stock was trading at $2.06 at the beginning of 2025. Since then, HILS shares have decreased by 16.0% and is now trading at $1.73.

When did Hillstream BioPharma IPO?

Hillstream BioPharma (HILS) raised $21 million in an initial public offering on Wednesday, January 12th 2022. The company issued 3,750,000 shares at $5.00-$6.00 per share.

How do I buy shares of Hillstream BioPharma?

Shares of HILS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Hillstream BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Hillstream BioPharma investors own include Absci (ABSI), Luminar Technologies (LAZR), Agnico Eagle Mines (AEM), Amprius Technologies (AMPX), atai Life Sciences (ATAI), HeartBeam (BEAT) and Biosig Technologies (BSGM).

Company Calendar

• Today: 7/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:HILS
• CIK: 1861657
• Web: www.hillstreambio.com
• Phone: 908-955-3140
• Fax: N/A
• Employees: 1
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.72)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$8.47 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -188.44%
• Return on Assets: -149.61%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.01
• Quick Ratio: 3.01

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.48 per share
• Price / Book: 3.69

Miscellaneous

• Outstanding Shares: 17,603,000
• Free Float: 12,280,000
• Market Cap: $31.16 million
• Optionable: Not Optionable
• Beta: 3.08